TY - JOUR
T1 - Advanced Parkinson's disease: Clinical characteristics and treatment (part 1)
AU - Kulisevsky, J.
AU - Burguera, J. A.
AU - Lezcano, E.
AU - Martínez-Torres, I.
AU - Carrillo, F.
AU - Chacón, J.
AU - Yañez, R.
AU - Castro, A.
AU - Arbelo, J. M.
AU - Valldeoriola-Serra, F.
AU - García-Ruiz, P. J.
AU - Luquin, M. R.
AU - Mir, P.
AU - Martinez-Castrillo, J. C.
AU - Puente, V.
AU - Sesar, A.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - Introduction: A large percentage of patients with Parkinson's disease (PD) develop motor fluctuations, dyskinesias, and severe non-motor symptoms within 3 to 5 years of starting dopaminergic therapy, and these motor complications are refractory to treatment. Several authors refer to this stage of the disease as advanced Parkinson's disease. Objective: To define the clinical manifestations of advanced PD and the risk factors for reaching this stage of the disease. Development: This consensus document has been prepared by using an exhaustive literature search and by discussion of the contents by an expert group on movement disorders of the Sociedad Española de Neurología (Spanish Neurology Society), coordinated by two of the authors (JK and MRL). Conclusions: Severe motor fluctuations and dyskinesias, axial motor symptoms resistant to levodopa, and cognitive decline are the main signs in the clinical phenotype of advanced PD. © 2013 Sociedad Española de Neurología.
AB - Introduction: A large percentage of patients with Parkinson's disease (PD) develop motor fluctuations, dyskinesias, and severe non-motor symptoms within 3 to 5 years of starting dopaminergic therapy, and these motor complications are refractory to treatment. Several authors refer to this stage of the disease as advanced Parkinson's disease. Objective: To define the clinical manifestations of advanced PD and the risk factors for reaching this stage of the disease. Development: This consensus document has been prepared by using an exhaustive literature search and by discussion of the contents by an expert group on movement disorders of the Sociedad Española de Neurología (Spanish Neurology Society), coordinated by two of the authors (JK and MRL). Conclusions: Severe motor fluctuations and dyskinesias, axial motor symptoms resistant to levodopa, and cognitive decline are the main signs in the clinical phenotype of advanced PD. © 2013 Sociedad Española de Neurología.
KW - Non-motor scales
KW - Motor scales
KW - Advanced Parkinson's disease
KW - Clinical phenotype
KW - Quality of life scales
KW - Risk factors
UR - https://dialnet.unirioja.es/servlet/articulo?codigo=4420877
U2 - 10.1016/j.nrl.2013.05.001
DO - 10.1016/j.nrl.2013.05.001
M3 - Article
SN - 0213-4853
VL - 28
SP - 503
EP - 521
JO - Neurologia
JF - Neurologia
IS - 8
ER -